Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Enterprise Value (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Enterprise Value for 7 consecutive years, with -$848.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Enterprise Value fell 73.56% to -$848.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$848.3 million, a 73.56% decrease, with the full-year FY2025 number at -$848.3 million, down 73.56% from a year prior.
  • Enterprise Value was -$848.3 million for Q4 2025 at Kymera Therapeutics, down from -$505.7 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$33.7 million in Q1 2022 to a low of -$848.3 million in Q4 2025.
  • A 5-year average of -$448.3 million and a median of -$462.2 million in 2021 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: skyrocketed 89.89% in 2022, then tumbled 1076.52% in 2023.
  • Kymera Therapeutics' Enterprise Value stood at -$442.4 million in 2021, then increased by 7.97% to -$407.2 million in 2022, then increased by 7.93% to -$374.9 million in 2023, then crashed by 30.37% to -$488.7 million in 2024, then tumbled by 73.56% to -$848.3 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Enterprise Value are -$848.3 million (Q4 2025), -$505.7 million (Q3 2025), and -$665.4 million (Q2 2025).